Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188719 · ClinicalTrials.gov registry record · Phase 1
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02188719 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 15 participants.
The verdict
NCT02188719, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is look at the safety of: * Taking a specific combination of immunosuppressant drugs after liver transplantation * Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells (darTregs) while taking this specific combination of drugs
Interventions
- DRUG Everolimus
- DRUG Tacrolimus
- DRUG Mycophenolate mofetil
- BIOLOGICAL Anti-Thymocyte Globulin - Rabbit
- BIOLOGICAL darTreg Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2019-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02188719
The ClinicalTrials.gov registry entry for NCT02188719 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Everolimus is the first listed.
NCT02188719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02188719 about?
NCT02188719 is a clinical study titled "Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation". The purpose of this study is look at the safety of: * Taking a specific combination of immunosuppressant drugs after liver transplantation * Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells (darTregs) while taking this specific combination of drugs
What is the current status of trial NCT02188719?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-12-17. Estimated completion is 2019-06-18.
What interventions are being tested in trial NCT02188719?
The interventions under investigation include: Everolimus (DRUG), Tacrolimus (DRUG), Mycophenolate mofetil (DRUG), Anti-Thymocyte Globulin - Rabbit (BIOLOGICAL), darTreg Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02188719?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.